• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

POLL: Which Adalimumab Biosimilar Will be Available First in 2023?

Article

Click here to answer this week's poll.

Which Adalimumab Biosimilar Will be Available First in 2023?

Hyrimoz (adalimumab-adaz)
Amjevita (adalimumab-atto)
Abrilada (adalimumab-afzb)
Yusimry (adalimumab-aqvh)
Related Videos
Related Content
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Article
US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

Article
© 2024 MJH Life Sciences

All rights reserved.